Guest
Guest
Mar 19, 2026
11:04 PM
|
There isn’t a clear public record showing **when Tadalafil 60?mg (marketed as variants like Vidalista 60?mg) specifically “gained data abstraction” or official clinical data status, because this strength is a generic, non?branded formulation produced by companies like Centurion Laboratories rather than an FDA?approved marketed drug with a formal regulatory timeline. Generic tadalafil products are typically introduced after the original branded drug’s patent expires, based on established data for the active ingredient itself rather than new clinical trial filings.
Tadalafil as a compound has been widely studied and approved for the treatment of Erectile Dysfunction and related conditions for many years, but specific generics like VIDALISTA 60 MG do not have the same kind of published approval history or distinct “data abstraction” date in major regulatory databases (e.g., US?FDA), because they are marketed internationally as generics rather than under a proprietary drug application.
In practice, Vidalista 60?mg appears on supplier/product listings and pharmacy offerings dating back at least a few years, and product pages show listings and updates as recently as early?2026, but this reflects commercial availability rather than a formal scientific data release event.
If you need scientific clinical data or regulatory approval history, that information would generally be found in published research on tadalafil itself or in official drug approval databases for branded products (such as Cialis), rather than for specific high?strength generic versions.
|
